S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What is the consumer staples sector?
6 best online and direct marketing retail stocks to invest in
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Last chance to set up your portfolio for OPEC cuts
What does consumer price index measure?

NeuroPace Stock Price, News & Analysis (NASDAQ:NPCE)

$8.22
-0.09 (-1.08%)
(As of 12/6/2023 ET)
Compare
Today's Range
$7.80
$8.32
50-Day Range
$5.90
$9.73
52-Week Range
$1.22
$9.73
Volume
47,515 shs
Average Volume
45,143 shs
Market Capitalization
$216.05 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.60

NeuroPace MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
16.8% Upside
$9.60 Price Target
Short Interest
Healthy
1.40% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.38mentions of NeuroPace in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$191,658 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($1.38) to ($1.16) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

377th out of 957 stocks

Surgical & Medical Instruments Industry

40th out of 78 stocks


NPCE stock logo

About NeuroPace Stock (NASDAQ:NPCE)

NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. The company's RNS system also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip leads and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

NPCE Stock Price History

NPCE Stock News Headlines

Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
Henry Ford Would NEVER Have Seen This Coming
In 1908, Henry Ford used a metal called vanadium in his Model T cars. Over a century later, automakers still turn to vanadium to make car bodies lighter and stronger. Today, this under-appreciated metal plays the starring role in cutting-edge battery tech set to revolutionize the energy storage market.
NeuroPace 10% Owner Trades $75K In Company Stock
OrbiMed Advisors LLC Reduces Stake in NeuroPace Inc
Morgan Stanley Upgrades NeuroPace (NPCE)
See More Headlines
Receive NPCE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NeuroPace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/07/2024

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NPCE
Fax
N/A
Employees
169
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.60
High Stock Price Target
$11.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+16.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-47,080,000.00
Pretax Margin
-62.96%

Debt

Sales & Book Value

Annual Sales
$60.20 million
Book Value
$1.40 per share

Miscellaneous

Free Float
19,056,000
Market Cap
$216.05 million
Optionable
Not Optionable
Beta
2.13
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














NPCE Stock Analysis - Frequently Asked Questions

Should I buy or sell NeuroPace stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NeuroPace in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" NPCE shares.
View NPCE analyst ratings
or view top-rated stocks.

What is NeuroPace's stock price target for 2024?

5 brokers have issued twelve-month price objectives for NeuroPace's shares. Their NPCE share price targets range from $9.00 to $11.00. On average, they expect the company's stock price to reach $9.60 in the next twelve months. This suggests a possible upside of 16.8% from the stock's current price.
View analysts price targets for NPCE
or view top-rated stocks among Wall Street analysts.

How have NPCE shares performed in 2023?

NeuroPace's stock was trading at $1.49 at the start of the year. Since then, NPCE stock has increased by 451.7% and is now trading at $8.22.
View the best growth stocks for 2023 here
.

Are investors shorting NeuroPace?

NeuroPace saw a decline in short interest during the month of November. As of November 15th, there was short interest totaling 151,000 shares, a decline of 61.8% from the October 31st total of 395,600 shares. Based on an average daily volume of 69,000 shares, the days-to-cover ratio is presently 2.2 days. Approximately 1.4% of the company's shares are sold short.
View NeuroPace's Short Interest
.

When is NeuroPace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 7th 2024.
View our NPCE earnings forecast
.

How were NeuroPace's earnings last quarter?

NeuroPace, Inc. (NASDAQ:NPCE) issued its earnings results on Monday, November, 6th. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.39) by $0.11. The firm earned $16.43 million during the quarter, compared to analysts' expectations of $14.23 million. NeuroPace had a negative net margin of 62.96% and a negative trailing twelve-month return on equity of 151.83%.

When did NeuroPace IPO?

(NPCE) raised $85 million in an initial public offering on Thursday, April 22nd 2021. The company issued 5,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley served as the underwriters for the IPO and Wells Fargo and SVB Leerink were co-managers.

Who are NeuroPace's major shareholders?

NeuroPace's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Morgan Stanley (9.13%), FMR LLC (2.69%), Kent Lake Capital LLC (2.19%), EAM Investors LLC (0.54%), Barclays PLC (0.04%) and Citigroup Inc. (0.01%). Insiders that own company stock include Accelmed Partners Ii LP, Frank M Fischer, Irina Ridley, Ltd Kck and Orbimed Advisors Llc.
View institutional ownership trends
.

How do I buy shares of NeuroPace?

Shares of NPCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:NPCE) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -